DXCM

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Dexcom Inc

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.
CEO
Kevin Sayer
Employees
5500
Headquarters

6340 Sequence Dr
San Diego, California 92121-4356
Phone: 18582000200
www.dexcom.com

News

Top 5 2nd Quarter Trades of DeepCurrents Investment Group LLC
Aug 16, 2022 05:00am

Related Stocks: JAZZ , FXI , PLUG , JBLU , DXCM ,


Source:GuruFocus
Quantinno Capital Management LP Buys 4, Sells 1 in 2nd Quarter
Aug 16, 2022 05:00am

Related Stocks: MSFT , AAPL , TSLA , AGCO , DXCM ,


Source:GuruFocus
3 Reasons to Buy the Dip With DexCom Stock
Aug 13, 2022 14:37pm

Its markets are growing steadily while its sales organization is spreading out worldwide.


Source:The Motley Fool
This Stock-Split Stock Is Up 30% Since Splitting Its Shares
Aug 11, 2022 14:07pm

DexCom has been doing better than big tech stocks that have had more notable stock splits this year.


Source:The Motley Fool
This Is, Hands Down, the Top Stock-Split Stock to Buy Right Now
Aug 08, 2022 09:21am

Alphabet, Amazon, DexCom, Shopify, and Tesla have all announced stock splits this year -- but only one of these giants is a screaming buy.


Source:The Motley Fool
Is it Still Worthy to Invest in DexCom (DXCM)?
Aug 06, 2022 02:55am

ClearBridge Investments, an investment management firm, published its “Large Cap Growth ESG Strategy” second quarter 2022 investor letter – a copy of which can be downloaded here. The ClearBridge Dividend Strategy outperformed its S&P 500 Index benchmark during the second quarter. On an absolute basis, the Strategy had gains in one of the 11 sectors […]


Source:Insider Monkey
The DexCom Inc. (DXCM) Stock Is Headed for a Correction
Aug 04, 2022 17:00pm

Currently, DexCom Inc.’s (DXCM) stock is trading at $88.13, marking a fall of -2.50% from last night’s close. At this price, the stock is -46.54% below its 52-week high of $164.86 and 31.75% above its 52-week low of $66.89. Based on the past 30-day period, the stock price is -1.76% below the high and +21.22% […]


Source:US Post News
Looking Into DexCom''s Return On Capital Employed
Aug 04, 2022 14:24pm

Pulled from Benzinga Pro data, DexCom (NASDAQ: DXCM ) showed a loss in earnings since Q1, totaling $50.90 million. Sales, on the other hand, increased by 10.08% to $692.20 million during Q2. DexCom reached earnings of $97.30 million and sales of $628.80 million in Q1. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests … Full story available on Benzinga.com


Source:Benzinga
Why Is Senseonics (SENS) Stock Heating Up Today?
Aug 04, 2022 13:58pm

Senseonics (NYSEAMERICAN: SENS ) stock jumped by over 50% after it announced its Eversense implantable glucose monitor was approved for coverage by Elevance Health (NYSE: ELV ), formerly known as Anthem. Senseonics had revenue of just $2.5 million in the first quarter. SENS stock’s latest move still leaves the market cap short of $1 billion. Hidden in the first-quarter numbers, however, was growth in U.S. sales, which could now climb rapidly. Senseonomics’ Eversense is offered in two versions: one that can run for 3 months and one that operates for 6 months . It competes with Abbott Laboratories’ (NYSE: ABT ) Freestyle Libre , which lasts 14 days . The Big Opportunity in Glucose Monitoring The market for glucose monitors was worth $11.7 billion in 2021 and is growing at over 7% per year. It includes devices that use testing strips, lancets, and continuous meters like the Eversense. I wrote about Senseonomics for Investorplace last December, when its stock price was at $2.67 and its market cap over $1 billion .


Source:InvestorPlace
Medical Sensors Market expected to Witness a Sustainable Growth over 2021-2031 | Cardiomo, Honeywell International, Inc., TE Connectivity, Dexcom, Inc.
Aug 04, 2022 05:19am

New York, 2022-Aug-04 — /EPR Network/ — Global Medical Sensors Market report from Global Insight Services is the single authoritative source of intelligence on Medical Sensors Market. [read full press release…]


Source:Express Press Release Distribution
DexCom PT Lowered to $100 at CFRA
Aug 02, 2022 16:30pm

https://www.investing.com/news/pro/dexcom-pt-lowered-to-100-at-cfra-432SI-2860807


Source:Investing.com
Dexcom One real-time CGM is now available on prescription in the UK
Aug 02, 2022 00:00am

Dexcom (Nasdaq:DXCM) announced that it made the Dexcom One real-time CGM (rt-CGM) available on prescription in the United Kingdom. The easy-to-use rt-CGM system will be available on prescription for everyone with type 1 or type 2 diabetes using insulin via the NHS England, Wales, Scotland and Northern Ireland drug tariff. According to a news release, […]


Source:WTWH
DexCom, Inc.: Dexcom ONE real-time Continuous Glucose Monitoring (rt-CGM) System available on prescription in the UK, improving access to rt-CGM for people with diabetes
Aug 01, 2022 23:04pm

The simple and easy to use Dexcom ONE rt-CGM system is now listed on the NHS England, Wales, Scotland and Northern Ireland drug tariffs The first of Dexcom''s scan-free and finger prick-free device…


Source:Finanz Nachrichten
DexCom, Inc.
Aug 01, 2022 23:02pm

Dexcom ONE real-time Continuous Glucose Monitoring System available on prescription in the UK, improving access to rt-CGM for people with diabetes. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy to use Dexcom ONE rt-CGM System on prescription via the NHS England, Wales, Scotland and Northern Ireland drug tariff to everyone with type 1 or type 2 diabetes using insulin. This marks the first time a rt-CGM, with no scanning and no finger pricks†, will be available to people with diabetes at the pharmacy level.


Source:Ad Hoc News
Dexcom ONE real-time Continuous Glucose Monitoring (rt-CGM) System available on prescription in the UK, improving access to rt-CGM for people with diabetes
Aug 01, 2022 23:00pm

LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy to use Dexcom ONE rt-CGM System on prescription via the NHS England, Wales, Scotland and Northern Ireland drug tariff to everyone with type 1 or type 2 diabetes using insulin. This marks the first time a rt-CGM, with no scanning and no finger pricks†, will be available to people with diabetes at t


Source:Business Wire
Insulet begins full market launch for Omnipod 5
Aug 01, 2022 00:00am

Insulet (Nasdaq:PODD) announced today that it commenced the full market launch for its next-generation Omnipod 5 system. The Omnipod 5 automated insulin delivery (AID) system has now been made fully available through U.S. retail pharmacy channels for individuals aged six years and older with type 1 diabetes. Get the full story at our sister site, Drug […]


Source:WTWH
Hot Stocks: CVX, FIVN rise on earnings; DXCM drop; RAD climbs on activist chatter
Jul 29, 2022 17:12pm

CVX and FIVN climbed on earnings news. DXCM declined on its quarterly update. RAD rose on speculation that the firm could become a target for activist investors.


Source:Seeking Alpha
Why DexCom Stock Is Falling Today
Jul 29, 2022 15:59pm

Investors didn''t like the company''s Q2 update.


Source:The Motley Fool
$100 Invested In This Stock 10 Years Ago Would Be Worth $3,000 Today
Jul 29, 2022 15:37pm

DexCom (NASDAQ: DXCM ) has outperformed the market over the past 10 years by 28.51% on an annualized basis producing an average annual return of 40.1%. Currently, DexCom has a market capitalization of $32.41 billion. Buying $100 In DXCM: If an … Full story available on Benzinga.com


Source:Benzinga
DexCom Shares Are Falling, but Analysts Still See a Winner
Jul 29, 2022 15:30pm

The developer of glucose-monitoring systems reported lower earnings and revenue than Wall Street expected.


Source:Barron''s
DexCom Tumbles 12% After Earnings Miss, Analysts Say Plunge ''Greatly Exaggerated''
Jul 29, 2022 13:33pm

https://www.investing.com/news/stock-market-news/dexcom-tumbles-12-after-earnings-miss-analysts-say-plunge-greatly-exaggerated-432SI-2858220


Source:Investing.com
DexCom PT Lowered to $105 at Oppenheimer; ''Buying on Weakness''
Jul 29, 2022 11:37am

https://www.investing.com/news/pro/dexcom-pt-lowered-to-105-at-oppenheimer-buying-on-weakness-432SI-2857967


Source:Investing.com
DexCom PT Lowered to $92 at BTIG
Jul 29, 2022 10:13am

https://www.investing.com/news/pro/dexcom-pt-lowered-to-92-at-btig-432SI-2857795


Source:Investing.com
DexCom PT Lowered to $112 at Stifel
Jul 29, 2022 07:38am

https://www.investing.com/news/pro/dexcom-pt-lowered-to-112-at-stifel-432SI-2857627


Source:Investing.com
DexCom (DXCM) Q2 2022 Earnings Call Transcript
Jul 29, 2022 02:00am

DXCM earnings call for the period ending June 30, 2022.


Source:The Motley Fool
Design tips for high-voltage protection in EVs and hybrids
Jul 29, 2022 00:00am

The primary goal of EV protective circuits: Keep vehicle occupants safe day-to-day and first-responders protected if the worst happens. Michael Zimmerman, Littelfuse, Inc. The 12-V automotive battery may become a relic of the past as electric vehicles (EV) and hybrid cars gain market share. EVs and hybrid vehicles use battery packs of at least 500-V […]


Source:WTWH
Dexcom to update next-gen G7 software, delaying FDA clearance, launch timelines
Jul 28, 2022 00:00am

The CEO of Dexcom (Nasdaq:DXCM) said today that the company’s regulatory path for the next-generation G7 has been slightly delayed. Speaking on the continuous glucose monitor (CGM) maker’s second-quarter earnings call, Dexcom Chair, President and CEO Kevin Sayer explained that the company has — based on feedback from the FDA — been tweaking the software of its next-generation […]


Source:WTWH
Dexcom stock dips on missed Q2 projections with broader G7 launch ‘in coming weeks’
Jul 28, 2022 00:00am

Dexcom (Nasdaq:DXCM) shares took a hit after hours today on second-quarter results that came up shy of the consensus forecast. Shares of DXCM were down 7.2% at $80.69 after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 2.4%. Get the full story at […]


Source:WTWH
DexCom Q2 2022 Earnings Preview
Jul 27, 2022 21:35pm

DexCom (DXCM) is scheduled to announce Q2 earnings results on Thursday, July 28th, after market close.The consensus EPS Estimate is $0.19 (-75.0% Y/Y) and the consensus Revenue Estimate…


Source:Seeking Alpha
2 Reasons Why DexCom Stock Could Be a Smart Buy This Week
Jul 27, 2022 17:53pm

Its global ambitions are poised to drive further returns.


Source:The Motley Fool
Nasdaq And 2 Other Stocks Insiders Are Selling
Jul 26, 2022 14:55pm

US gold futures traded mostly flat on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga''s insider transactions platform. DexCom The Trade: DexCom, Inc. (NASDAQ: DXCM ) EVP Managing Director Dexcom V Steven R Pacelli sold a total of 1,000 shares at an … Full story available on Benzinga.com


Source:Benzinga
mHealth Apps Market is projected to expand at a steady CAGR over the forecast by 2031 | Bayer Healthcare, Boston Scientific Corporation, Dexcom, Inc.
Jul 22, 2022 10:00am

New York, 2022-Jul-14 — /EPR Network/ — Global mHealth Apps Market report from Global Insight Services is the single authoritative source of intelligence on mHealth [read full press release…]


Source:Express Press Release Distribution
Research and Markets: United Kingdom Glucometers Market Report 2022-2027: Key Players Abbott Laboratories, Medtronic, Roche Diagnostics, Dexcom & Dr.Morpen Leading Robust Growth in Sector - ResearchAndMarkets.com
Jul 22, 2022 09:16am

The "United Kingdom Glucometers Market, By Product Type (Self Glucose Monitoring Glucometers v/s Continuous Glucose Monitoring Glucometers), By Technique, By Type, By Distribution Channel, By End …


Source:Finanz Nachrichten
United Kingdom Glucometers Market Report 2022-2027: Key Players Abbott Laboratories, Medtronic, Roche Diagnostics, Dexcom & Dr.Morpen Leading Robust Growth in Sector - ResearchAndMarkets.com
Jul 22, 2022 09:11am

DUBLIN--(BUSINESS WIRE)--The "United Kingdom Glucometers Market, By Product Type (Self Glucose Monitoring Glucometers v/s Continuous Glucose Monitoring Glucometers), By Technique, By Type, By Distribution Channel, By End User, By Region, Competition Forecast & Opportunities, 2027" report has been added to ResearchAndMarkets.com''s offering. United Kingdom glucometers market is expected to witness robust growth in the forecast period. Rapidly changing lifestyles and growing requirements for a


Source:Business Wire
3 Biotech Stocks to Buy on the Dip
Jul 21, 2022 11:45am

With a rebound likely , investors are looking for biotech stocks to buy on the dip. According to Investor’s Business Daily, there’s been a collective 22.5% surge among the biotech stocks they’re tracking. Still, the sector is well below its 2021 highs, making this a great time to buy biotech stocks on the dip. Moreover, the sector’s stocks are well-positioned to keep climbing for a long time. That’s because the key factor that had been pushing them down for a long time –fears of sky-high interest rates –is receding. 7 Cheap Stocks That Are Trading at a Discount This situation has arisen because core inflation appears to have peaked and gasoline prices are retreating. As a result, overall inflation is about to drop, and the Fed will not have to raise rates tremendously. With that in mind, these are the three biotech stocks to buy on the dip: GSK GSK $20.47 Dexco DXCM $82.18 Schrodinger SDGR $32.67 GSK (GSK) Source: Willy Barton / Shutterstock.com Trial results of the GSK (NYSE: GSK ) dostarlimab drug suggest that the product is well-positioned to become “a blockbuster” cancer treatment.


Source:InvestorPlace
Dexcom Canada Achieves Great Place to Work Certification
Jul 19, 2022 10:00am

Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that it is certified as a Great Place to Work in Canada for 2022-23. Awarded by Great Place to Work Institute Canada, the global authority on high-trust, high-performance workplace cultures, this prestigious certification is based on direct feedback from employees and demonstrates


Source:Wallstreet:Online
Better Bear Market Buy: DexCom vs. Intuitive Surgical
Jul 16, 2022 10:04am

Both of these disruptive healthcare companies could be big winners over the long term.


Source:The Motley Fool
Bernstein initiates DexCom with an outperform rating, citing long growth runway
Jul 15, 2022 18:13pm

DexCom (DXCM) stock rose as much as 4% to $79.55 in Friday trading, with shares helped by Bernstein research initiating the company with an outperform rating


Source:Seeking Alpha
Is DexCom Stock Too Pricey to Buy?
Jul 15, 2022 15:30pm

Its valuation is expensive, but its future is quite bright.


Source:The Motley Fool
Bernstein calls medical tech company Dexcom a clear buy, citing a long-term runway for diabetes management
Jul 15, 2022 12:00pm

Bernstein launched coverage of medical tech company Dexcom, which makes devices for people with diabetes, with an outperform rating and $105 price target.


Source:CNBC
This Stock-Split Stock Is a Better Buy Than GameStop
Jul 14, 2022 14:37pm

DexCom is more of a sure thing in the long run.


Source:The Motley Fool
New filing by DEXCOM, INC. POLITICAL ACTION COMMITTEE (DEXCOM PAC)
Jul 13, 2022 18:54pm

The DEXCOM, INC. POLITICAL ACTION COMMITTEE (DEXCOM PAC) successfully filed their F3XN JULY QUARTERLY with the coverage period of 04/01/2022 to 06/30/2022 and a confirmation ID of FEC-1609958 *********CommitteeId: C00770222 | FilingId: 1609958 | FormType: F3XN | CoverageFrom: 04/01/2022 | CoverageThrough: 06/30/2022 | ReportType: JULY QUARTERLY*********


Source:The FEC
Here''s How Much $100 Invested In DexCom 15 Years Ago Would Be Worth Today
Jul 13, 2022 15:03pm

DexCom (NASDAQ: DXCM ) has outperformed the market over the past 15 years by 20.1% on an annualized basis producing an average annual return of 26.25%. Currently, DexCom has a market capitalization of $30.62 billion. Buying $100 In DXCM: If an … Full story available on Benzinga.com


Source:Benzinga
DexCom Stock: Long Term Secular Growth Beneficiary (NASDAQ:DXCM)
Jul 08, 2022 19:06pm

DexCom has a leading position in a huge and growing market of continuous glucose monitoring. Read more to see why DXCM stock is a strong buy.


Source:Seeking Alpha
Use This Chart Pattern To Know When Stocks Have Topped And You Can Sell Short
Jul 07, 2022 18:05pm

This chart pattern predicted the breakdown of Dexcom in 2021. Here''s how you can use it to sell stocks short.


Source:Investor''s Business Daily
DexCom Stock: I Wouldn''t Buy The Dip (NASDAQ:DXCM)
Jul 07, 2022 11:50am

DexCom''s (DXCM) growth rates are slowing down, yet it is still reporting impressive top-line numbers. See why I DXCM stock remains a Sell in my opinion.


Source:Seeking Alpha
Dexcom Schedules Second Quarter 2022 Earnings Release and Conference Call for July 28, 2022 at 4:30 p.m. Eastern Time.
Jun 30, 2022 20:04pm

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2022 financial results after market close on Thursday, July 28, 2022. Management will hold a conference call to review the company''s second quarter 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will


Source:Business Wire
DexCom''s Stock Split Is Complete: Is It Time to Buy?
Jun 27, 2022 14:45pm

Many people will keep up their spending on treating chronic conditions, regardless of economic pressures.


Source:The Motley Fool